Bjork Elisabeth (Director) sold $2.0M of stock
SEC Form 4
Pharvaris N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Pharvaris N.V. valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 11 selling0 purchases and 68 sales by directors and officers, last 12 monthsInsider trades
- Funds72 adding, 42 cuttingOf 37 active managers that changed their stake, 25 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 18.8% while net income fell 36.8%: a 18pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Pharvaris N.V.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 9.5% in a year.
- Insiders selling. 11 insiders sold $33M of stock over the past 365 days and none bought (48% under pre-set trading plans).
Latest results
- Earnings per share
- -$0.70 against an average estimate of -$0.65: missed by 7.1%
- Next report
- November 12, 2026
Price chart
- 1 day0.0%
- 1 week+6.3%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $-3.36
Growth
- Share count change
- +9.5%
Cash
- Free cash flow (TTM)
- -$155M
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Insider trade
- Insider trade
Schikan Johannes Gerardus Christiaan Petrus (Director) sold $7.0M of stock
SEC Form 4 - Insider trade
Lu Peng (President) sold $3.5M of stock
SEC Form 4 - Insider trade
Abele Stefan Andreas (Chief Technical Ops Officer) sold $1.8M of stock
SEC Form 4 - Insider trade
Lesage Anne (Chief Early Development) sold $1.1M of stock, under a pre-arranged trading plan
SEC Form 4
Valuation models
We value Pharvaris N.V. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no positive earnings in the latest twelve months |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: the model gives no positive value |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: return on equity is not positive |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no positive revenue in the latest twelve months |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Pharvaris N.V. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, before the open.
Analysts' consensus
No analyst estimates are published for Pharvaris N.V.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.65 | −$0.70 | −7.1% |
| Dec 2025 | −$0.62 | −$0.71 | −15.4% |
| Sept 2025 | −$0.67 | −$0.60 | +10.7% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 4.3% of tradable shares
- Days to cover
- 3.4 at average volume
- Short interest, 1 month
- +38% to October 15, 2026
- Held by institutions
- 93% of shares
- Held by insiders
- 6.3% of shares
- Employees
- 148 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial health
- Short-term assets cover short-term liabilities The company doesn't report a short-term split. Not assessable.
- Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
- More cash than debt Cash or debt not separately reported. Not assessable.
- Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
- Operating profit covers interest at least five times over Operating income of −$196m against $484,863 of interest.
Dividends, buybacks and capital spending
- Diluted share count
- +9.5%
- year over year
Who owns it
Funds buying and selling- Reported value
- $2.2B
- Institutions reporting
- 125
- Shares held vs prior quarter
- ▲ 9.3%
- Positions opened / closed
- 23 / 9
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| FMR LLC | $227M | 6.6M | 10.1% | ▲ 4.5% |
| General Atlantic, L.P. | $227M | 6.6M | 10.1% | ▼ 18.4% |
| Foresite Capital Management Iv, LLC | $165M | 4.8M | 7.4% | 0.0% |
| Venbio Partners LLC | $161M | 4.6M | 7.2% | ▲ 0.1% |
| Viking Global Investors LP | $126M | 3.7M | 5.6% | 0.0% |
| Eqt Fund Management S.A R.L. | $118M | 3.4M | 5.3% | 0.0% |
| Deerfield Management Company, L.P. | $117M | 3.4M | 5.2% | ▲ 8.0% |
| Bain Capital Life Sciences Investors, LLC | $92.5M | 2.7M | 4.1% | 0.0% |
| Wellington Management Group LLP | $82.7M | 2.4M | 3.7% | ▲ 12.9% |
| Polar Capital Holdings PLC | $80.4M | 2.3M | 3.6% | ▲ 197.9% |
| Point72 Asset Management, L.P. | $56.8M | 1.6M | 2.5% | ▲ 63.0% |
| Commodore Capital LP | $49.3M | 1.4M | 2.2% | ▼ 25.7% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Pharvaris N.V.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $32.7M 68 trades by 11 insiders · 48% under pre-set plans
Net ▼ $32.7M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Monges Viviane Director | September 23, 2026 | Sell | 11,969 | $33.05 | $395,575 |
| Schikan Johannes Gerardus Christiaan Petrus Director | September 22, 2026 | Sell | 800 | $36.19 | $28,952 |
| Nassif David W. CFO / CLO | September 21, 2026 | Sell | 6,000 | $36.47 | $218,820 |
| Lesage Anne Chief Early Development | September 17, 2026 | Sell | 20,000 | $38.27 | $765,400 |
| Glassman Robert Director | September 17, 2026 | Sell pre-set plan | 14,493 | $38.56 | $558,850 |
| Bjork Elisabeth Director | September 17, 2026 | Sell | 52,500 | $37.89 | $2M |
| Schikan Johannes Gerardus Christiaan Petrus Director | September 17, 2026 | Sell | 200,000 | $35.00 | $7M |
| Lu Peng President | September 17, 2026 | Sell | 100,000 | $35.00 | $3.5M |
| Souverijns Wim Chief Commercial Officer | September 15, 2026 | Sell pre-set plan | 6,090 | $38.99 | $237,449 |
| Glassman Robert Director | September 15, 2026 | Sell pre-set plan | 8,667 | $38.27 | $331,686 |
| Abele Stefan Andreas Chief Technical Ops Officer | September 15, 2026 | Sell | 45,000 | $38.14 | $1.7M |
| Abele Stefan Andreas Chief Technical Ops Officer | September 15, 2026 | Sell | 1,400 | $39.24 | $54,936 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Pharvaris N.V. in brief
- What does Pharvaris N.V. do?
- Pharvaris N.V. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Pharvaris N.V.'s stock ticker?
- Pharvaris N.V. trades under the ticker PHVS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Pharvaris N.V.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, General Atlantic, L.P. and Foresite Capital Management Iv, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Pharvaris N.V. stock?
- Over the last 12 months, Pharvaris N.V.'s directors and officers reported 0 open-market purchases and 68 sales on Form 4. The insider trading page charts every trade.
- When is Pharvaris N.V.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Pharvaris N.V. announces its own schedule.
Follow research on Pharvaris N.V.
New research on the companies we cover arrives in the weekly email. Free, one email a week.